ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus

ClinicalTrials.gov ID: NCT07205900

Public ClinicalTrials.gov record NCT07205900. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 20, 2026, 7:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate Efficacy, Safety, and Tolerability of HM15275 for 36 Weeks in Obese or Overweight Subjects Without Diabetes Mellitus

Study identification

NCT ID
NCT07205900
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Enrollment
267 participants

Conditions and interventions

Interventions

  • HM15275 Drug
  • Placebo of HM15275 Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Not listed

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 1, 2025
Primary completion
Dec 31, 2026
Completion
Dec 31, 2026
Last update posted
Apr 7, 2026

2025 – 2027

United States locations

U.S. sites
14
U.S. states
7
U.S. cities
13
Facility City State ZIP Site status
ProSciento Inc Chula Vista California 91911
Accellacare of Duly - Duly Oak Lawn Oak Lawn Illinois 60453
Accellacare of McFarland Ames Iowa 50010
Accellacare of Cary - Cary Medical Group Cary North Carolina 27511
Accellacare of Hickory Hickory North Carolina 28601
Raleigh Medical Group, P.A. Raleigh North Carolina 27609
Accellacare of Piedmont - Piedmont HealthCare Statesville North Carolina 28626
Accellacare of Wilmington, LLC Wilmington North Carolina 28401
Accellacare of Winston Salem Winston-Salem North Carolina 27103
Accellacare of Charleston Mt. Pleasant South Carolina 29464
Accellacare of Bristol-PAC of Tennessee Bristol Tennessee 37620
Bristol-Internal Medicine and Pediatric Associates of Bristol, P.C. Bristol Tennessee 37620
Texas Clinical Research Institute Arlington Texas 76012
Velocity Clinical Research, Dallas Dallas Texas 75230

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07205900, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 7, 2026 · Synced Apr 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07205900 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →